News & Events about Ventyx Biosciences Inc.
Ticker Report
2 months ago
Ventyx Biosciences (NASDAQ:VTYX Get Rating) had its price target trimmed by Oppenheimer from $65.00 to $62.00 in a research report report published on Friday, Benzinga reports. The brokerage currently has an outperform rating on the stock. Oppenheimer also issued estimates for Ventyx ...
Ticker Report
2 months ago
Ventyx Biosciences, Inc. (NASDAQ:VTYX Get Rating) Stock analysts at Oppenheimer issued their FY2026 EPS estimates for shares of Ventyx Biosciences in a report issued on Sunday, March 19th. Oppenheimer analyst J. Jones forecasts that the company will post earnings per share of ($2.75...
Globe Newswire
2 months ago
ENCINITAS, Calif., March 24, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (Ventyx), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that ...
Globe Newswire
2 months ago
ENCINITAS, Calif., March 11, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (Ventyx), has learned that Silicon Valley Bank (SVB) has been closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation (FDIC) as ...
Ticker Report
4 months ago
Ventyx Biosciences, Inc. (NASDAQ:VTYX Get Rating) Director William Richard White sold 33,353 shares of the firms stock in a transaction that occurred on Monday, January 23rd. The shares were sold at an average price of $35.10, for a total value of $1,170,690.30. The transaction was ...